Browse hierarchy: [Hematology (HE)](/submissions/HE) → [Subpart J — Products Used In Establishments That Manufacture Blood and Blood Products](/submissions/HE/subpart-j%E2%80%94products-used-in-establishments-that-manufacture-blood-and-blood-products) → [21 CFR 864.9245](/submissions/HE/subpart-j%E2%80%94products-used-in-establishments-that-manufacture-blood-and-blood-products/864.9245) → PMQ — Peripheral Blood Processing Device For Wound Management

# PMQ · Peripheral Blood Processing Device For Wound Management

_Hematology · 21 CFR 864.9245 · Class 2_

**Canonical URL:** https://fda-staging.innolitics.com/productcode/PMQ

## Overview

- **Product Code:** PMQ
- **Device Name:** Peripheral Blood Processing Device For Wound Management
- **Regulation:** [21 CFR 864.9245](/submissions/HE/subpart-j%E2%80%94products-used-in-establishments-that-manufacture-blood-and-blood-products/864.9245)
- **Device Class:** 2
- **Review Panel:** [Hematology](/submissions/HE)

## Identification

An automated blood cell separator is a device that uses a centrifugal or filtration separation principle to automatically withdraw whole blood from a donor, separate the whole blood into blood components, collect one or more of the blood components, and return to the donor the remainder of the whole blood and blood components. The automated blood cell separator device is intended for routine collection of blood and blood components for transfusion or further manufacturing use.

## Classification Rationale

Class II (special controls). The special control for this device is a guidance for industry and FDA staff entitled “Class II Special Controls Guidance Document: Automated Blood Cell Separator Device Operating by Centrifugal or Filtration Separation Principle.”

## Special Controls

*Classification.* Class II (special controls). The special control for this device is a guidance for industry and FDA staff entitled “Class II Special Controls Guidance Document: Automated Blood Cell Separator Device Operating by Centrifugal or Filtration Separation Principle.”

## Recent Cleared Devices (3 of 3)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [BK251232](/device/BK251232.md) | PRF-Matrix System | Royal Wound-X, Inc. Hackensack, NJ 07061 | Feb 20, 2026 | SESE |
| [BK251174](/device/BK251174.md) | FastSkin Patch | MimiX Biotherapeutics, Ltd | Nov 7, 2025 | SESE |
| [BK241079](/device/BK241079.md) | Peripheral blood processing device for wound management | Innoveren Scientific, Inc. Cincinnati, OH | Mar 28, 2025 | SESE |

## Top Applicants

- Innoveren Scientific, Inc. Cincinnati, OH — 1 clearance
- MimiX Biotherapeutics, Ltd — 1 clearance
- Royal Wound-X, Inc. Hackensack, NJ 07061 — 1 clearance

---

**Source:** [https://fda-staging.innolitics.com/productcode/PMQ](https://fda-staging.innolitics.com/productcode/PMQ)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com